Seeking Alpha

Pharmacyclics (PCYC +9.5%) trades higher today after RBC Capital ups the shares to Outperform...

Pharmacyclics (PCYC +9.5%) trades higher today after RBC Capital ups the shares to Outperform and raises its price target to $100 from $70. The firm cites optimism over a number of upcoming catalysts for its leukemia drug Ibrutnib, which is being jointly developed by PCYC and JNJ's Janssen Pharmaceuticals.
Comments (1)
  • A SMARTER GREEK
    , contributor
    Comments (16) | Send Message
     
    Mr. Duggan the CEO and Chairman..is repeating again with a phenominlal product(s), and successfull company in PCYC as he did
    with ISRG..from 12 to 500!
    Real company, great products, good management..de ja vu!
    13 May 2013, 01:17 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|